Vasopressin

Its molecular weight is 1084.23 having an amino acid sequence of Cys-Tyr-Phe-Gln-Asn-Pro-Lys-Arg-NH2 and a molecular formula: C46H65N15O12S2.\n\nDimers and Aggregates: \nLess than 1% as determined by silver-stained SDS-PAGE gel analysis.\n\nEndotoxin: \n(same/less than) 0.1ng/ug (IEU/ug) of Vasopressin.\n\nSolubility: \nIt is recommended to reconstitute the lyophilized Vasopressin in sterile 18MOmega-cm H2O not less than 100microg/ml, which can then be further diluted to other aqueous solutions.\n\nStability: \nLyophilized Vasopressin although stable at room temperature for 3 weeks, should be stored desiccated below -180C. Upon reconstitution Vasopressin should be stored at 40C between 2-7 days and for future use below -180C. For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA). Please avoid freeze-thaw cycles.

Prices direct from United States Biological

Quick response times

Exclusive Biosave savings/discounts

SPECIFICATIONS

Catalog Number

V2120-10

Size

5mg

Form

Supplied as a lyophilized powder without additives.

Purity

(same/more than) 98% as determined by RP-HPLC, anion-exchange FPLC and/or reducing and non-reducing SDS-PAGE Silver Stained gel.

References

1. Decrease in nocturnal urinary levels of arginine vasopressin in patients with nocturnal polyuria.\n\nUrology 2006 Jun 24;\n\n2. 1-Deamino (8-D-arginine) vasopressin infusion partially corrects platelet deposition on subendothelium in Bernard-Soulier syndrome: the role of factor VIII.\n\nPlatelets 1999 Apr;10(2):141-5\n\n3. Vasopressin treatment for cyclic antidepressant overdose.\n\nJ Emerg Med 2006 Jul;31(1):65-8\n\n4. Drugs of the future: vasopressin antagonists.\n\nCell Mol Life Sci 2006 Jun 23;\n\n5. The use of vasopressin bolus to treat refractory hypotension secondary to reperfusion during orthotopic liver transplantation.\n\nAnesth Analg 2006 Jul;103(1):261\n\n6. Neuro-immune-endocrine mechanisms during septic shock: role for nitric oxide in vasopressin and oxytocin release.\n\nEndocr Metab Immune Disord Drug Targets 2006 Jun;6(2):137-42